First Clinical Trial in MOGAD Meets Primary Endpoint
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Satralizumab reduced the risk of…
:max_bytes(150000):strip_icc()/CopyofHDCRecallFullBleedStockPhotoRedBadge-4f514b52c8384bdba04ebeebf96589b9.png?w=390&resize=390,220&ssl=1 "Blueberries, Turkey Bacon, and More Pulled From Shelves This Week")
